Search
- Page Path
- HOME > Search
- Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide
- Yeonju Kim, Eun-Jin Kim, Sang-Won Lee, Donghyok Kwon
- Osong Public Health Res Perspect. 2021;12(3):139-148. Published online June 24, 2021
- DOI: https://doi.org/10.24171/j.phrp.2021.0037
- 6,479 View
- 151 Download
- 8 Web of Science
- 9 Crossref
-
Abstract
PDF - The variant B.1.1.7 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the RNA virus causing the pandemic more than a year worldwide, was reported from United Kingdom (UK) in late December 2020. It was reported that mortality increases by 65% and transmissibility increases by 70%, which may result in an increase of reproduction number to 1.13−1.55 from 0.75−0.85. To analyze the global increasing trend of the variant B.1.1.7, we extracted results of B.1.1.7 from GISAID on May 11 and May 12, 2021, and conducted a doseresponse regression. It took 47 days to reach 20% and 121 days to reach 50% among the sequence submitted from UK. In Korea, cases of B.1.1.7 have increased since the first report of three cases on December 28, 2020. Positive rate of B.1.1.7 in Korea was 21.6% in the week from May 9 to May 15, 2021. Detection rate of the variants is expected to increase further and new variants of SARS-CoV-2 are emerging, so a close monitoring and control would be maintained for months.
-
Citations
Citations to this article as recorded by
- Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Ahmed I. Abulsoud, Hussein M. El-Husseiny, Ahmed A. El-Husseiny, Hesham A. El-Mahdy, Ahmed Ismail, Samy Y. Elkhawaga, Emad Gamil Khidr, Doaa Fathi, Eman A. Mady, Agnieszka Najda, Mohammad Algahtani, Abdulrahman Theyab, Khalaf F. Alsharif, Ashraf Albrakati
Biomedicine & Pharmacotherapy.2023; 157: 113977. CrossRef - Structural implications of SARS-CoV-2 Surface Glycoprotein N501Y mutation within receptor-binding domain [499-505] – computational analysis of the most frequent Asn501 polar uncharged amino acid mutations
Done Stojanov
Biotechnology & Biotechnological Equipment.2023;[Epub] CrossRef - Molecular and Clinical Epidemiology of SARS-CoV-2 Infection among Vaccinated and Unvaccinated Individuals in a Large Healthcare Organization from New Jersey
José R. Mediavilla, Tara Lozy, Annie Lee, Justine Kim, Veronica W. Kan, Elizabeth Titova, Ashish Amin, Michael C. Zody, André Corvelo, Dayna M. Oschwald, Amy Baldwin, Samantha Fennessey, Jerry M. Zuckerman, Thomas Kirn, Liang Chen, Yanan Zhao, Kar Fai Cho
Viruses.2023; 15(8): 1699. CrossRef - Incidence Evaluation of SARS-CoV-2 Variants in the Ulsan Area, Korea, Using PowerChek SARS-CoV-2 S-gene Mutation Detection Kit: A Pilot Study
Sang Hyuk Park, Hyun-Ki Kim, Hang Kang, Jung Heon Kim, Jaeseung Lee, Ji-Hun Lim, Seon-Ho Lee, Joseph Jeong
Annals of Laboratory Medicine.2022; 42(3): 363. CrossRef - Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Reem Hoteit, Hadi M. Yassine
Vaccines.2022; 10(6): 919. CrossRef - Virtual recruitment and participant engagement for substance use research during a pandemic
Carolin C. Hoeflich, Anna Wang, Ayodeji Otufowora, Linda B. Cottler, Catherine W. Striley
Current Opinion in Psychiatry.2022; 35(4): 252. CrossRef - Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface
Hongguan Xing, Liyan Zhu, Pingping Wang, Guoping Zhao, Zhihua Zhou, Yi Yang, Hong Zou, Xing Yan
Frontiers in Immunology.2022;[Epub] CrossRef - Mutations in SARS-CoV-2 nucleocapsid in variants of concern impair the sensitivity of SARS-CoV-2 detection by rapid antigen tests
Ibrahim T. Hagag, Krzysztof Pyrc, Saskia Weber, Anne Balkema-Buschmann, Martin H. Groschup, Markus Keller
Frontiers in Virology.2022;[Epub] CrossRef - The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern
Lixin Lin, Ying Liu, Xiujuan Tang, Daihai He
Frontiers in Public Health.2021;[Epub] CrossRef
- Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
- 2019 Tabletop Exercise for Laboratory Diagnosis and Analyses of Unknown Disease Outbreaks by the Korea Centers for Disease Control and Prevention
- Il-Hwan Kim, Jun Hyeong Jang, Su-Kyoung Jo, Jin Sun No, Seung-Hee Seo, Jun-Young Kim, Sang-Oun Jung, Jeong-Min Kim, Sang-Eun Lee, Hye-Kyung Park, Eun-Jin Kim, Jun Ho Jeon, Myung-Min Choi, Boyeong Ryu, Yoon Suk Jang, Hwami Kim, Jin Lee, Seung-Hwan Shin, Hee Kyoung Kim, Eun-Kyoung Kim, Ye Eun Park, Cheon-Kwon Yoo, Sang-Won Lee, Myung-Guk Han, Gi-Eun Rhie, Byung Hak Kang
- Osong Public Health Res Perspect. 2020;11(5):280-285. Published online October 22, 2020
- DOI: https://doi.org/10.24171/j.phrp.2020.11.5.03
- 5,866 View
- 106 Download
-
Abstract
PDF
Objectives The Korea Centers for Disease Control and Prevention has published “A Guideline for Unknown Disease Outbreaks (UDO).” The aim of this report was to introduce tabletop exercises (TTX) to prepare for UDO in the future.
Methods The UDO Laboratory Analyses Task Force in Korea Centers for Disease Control and Prevention in April 2018, assigned unknown diseases into 5 syndromes, designed an algorithm for diagnosis, and made a panel list for diagnosis by exclusion. Using the guidelines and laboratory analyses for UDO, TTX were introduced.
Results Since September 9th, 2018, the UDO Laboratory Analyses Task Force has been preparing TTX based on a scenario of an outbreak caused by a novel coronavirus. In December 2019, through TTX, individual missions, epidemiological investigations, sample treatments, diagnosis by exclusions, and next generation sequencing analysis were discussed, and a novel coronavirus was identified as the causal pathogen.
Conclusion Guideline and laboratory analyses for UDO successfully applied in TTX. Conclusions drawn from TTX could be applied effectively in the analyses for the initial response to COVID-19, an ongoing epidemic of 2019 – 2020. Therefore, TTX should continuously be conducted for the response and preparation against UDO.
First
Prev
